6-8
Oct
2026
3PBIOVIAN
About 3PBIOVIAN
Certifications
-
FDA -
GMP
Categories
Meet us at
-
CPHI Milan 2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
-
Country/Region:Spain
-
On CPHI since:2015
-
Certificates:3
-
Employees:500 - 999
Company types
Primary activities
Contact info
-
-
-
Pol Mocholí, Calle Mocholí 2, 31110, Noáin, Navarra, Spain
Products from 3PBIOVIAN (5)
3PBIOVIAN Resources (10)
-
News Rokote Laboratories signs an agreement with 3PBIOVIAN for GMP manufacturing of adenovirus vector-based COVID-19 vaccine
Rokote Laboratories Finland Ltd. has selected 3PBIOVIAN as their CDMO partner for GMP manufacturing of adenovirus type 5 (Ad5) vector-based candidate expressing a modified spike protein of severe acute respiratory coronavirus 2 (SARS-CoV-2).
-
Brochure 3P Biopharmaceuticals and Biovian join forces to create 3PBIOVIAN, a leading pa
Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced their combination. -
News 3P Biopharmaceuticals and Biovian join forces to create 3PBIOVIAN, a leading pan-European biologics CDMO
Paris, February 1, 2024 - Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced today their combination to establish a new pan-European leader in their field. Backed by their common shareholder, Keensight Capital, one of the leading private equity funds dedicated to pan-European Growth Buyout[[1]] investments, the combination of Biovian and 3P further extends the group’s value proposition to address complex customer needs across the entire development cycle.
[1] Growth Buyout: investment in profitable, private companies experiencing strong growth, in minority or majority positions, with or without leverage, using a flexible approach tailored to the needs of individual entrepreneurs, in order to finance organic growth projects, acquisition strategies or provide historic shareholders with liquidity.
-
Brochure Rokote Laboratories signs an agreement with 3PBIOVIAN for GMP manufacturing of a
Rokote Laboratories Finland Ltd. has selected 3PBIOVIAN as their CDMO partner for GMP manufacturing of adenovirus type 5 (Ad5) vector-based candidate. -
Brochure AAVion flyer
From plasmid to vial, our proprietary AAVion® platformpropels your path to clinical success. -
Brochure Analytical Services 3PBIOVIAN Flyer
With decades of experience, specialized know-how, and state-of-the-art facilities,we’re the CDMO partner you can count on for biologics and advanced therapies. -
Brochure Mammalian 3PBIOVIAN Flyer
Choose our Mammalian CDMO services toproduce your recombinant proteins and antibodies. -
Brochure Microbial 3PBIOVIAN Flyer
Choose our Microbial CDMO servicesfor recombinant protein production using bacterialand yeast cell lines. -
Brochure pDNA 3PBIOVIAN Flyer
Plasmid DNA (pDNA) is a critical raw material for viral vectorproduction, such as adeno-associated virus (AAV), as well asnon-viral gene therapy, and DNA or mRNA vaccine development. Whether youneed research-grade (RG), high-quality (HQ), or GMP-grade pDNA, we deliverthe experience and quality your project needs. -
Brochure Viral Analytics Services
We understand that time, cost, and quality are not justpriorities - they are critical to your success. That’s whywe are committed to delivering tailored, flexible, andcost-effective solutions that meet your needs, withoutcompromise.